_id
691056ebccc777a4e85d5656
Ticker
CTXR
Name
Citius Pharmaceuticals Inc
Exchange
NASDAQ
Address
11 Commerce Drive, Cranford, NJ, United States, 07016
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://citiuspharma.com
Description
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Last Close
1.16
Volume
539282
Current Price
1.12
Change
-3.4482758620689493
Last Updated
2025-11-29T11:59:04.684Z
Image
-
Ipo Date
2017-07-06T00:00:00.000Z
Market Cap
26599958
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.984
Sentiment Sources
1
Rating
4
Target Price
6
Strong Buy
1
Buy
0
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
0
Cost Of Revenue
41367
Gross Profit
-41367
Operating Expenses
8746640
Operating Income
-8788007
Interest Expense
172262
Pretax Income
-8939632
Net Income
-8789872
Eps
-0.7985786365202324
Dividends Per Share
-
Shares Outstanding
18472191
Income Tax Expense
264240
EBITDA
-8726003
Operating Margin
-
Total Other Income Expense Net
-151625
Cash
6089126
Short Term Investments
-
Receivables
-
Inventories
17208967
Total Current Assets
24611269
Property Plant Equipment
880732
Total Assets
127676859
Payables
10094042
Short Term Debt
229388
Long Term Debt
-
Total Liabilities
60115929
Equity
65058550
Depreciation
41367
Change In Working Capital
771971
Cash From Operations
-5406620
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
11469336
Net Change In Cash
6062716
PE
-
PB
0.18948660122305216
ROE
-13.510709968174822
ROA
-6.884467607399396
FCF
-5406620
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
4.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2
Value Investing Score
4.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
41367
Quarters > 0 > income Statement > gross Profit
-41367
Quarters > 0 > income Statement > operating Expenses
8746640
Quarters > 0 > income Statement > operating Income
-8788007
Quarters > 0 > income Statement > interest Expense
172262
Quarters > 0 > income Statement > pretax Income
-8939632
Quarters > 0 > income Statement > net Income
-8789872
Quarters > 0 > income Statement > eps
-0.7985786365202324
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
11006896
Quarters > 0 > income Statement > income Tax Expense
264240
Quarters > 0 > income Statement > EBITDA
-8726003
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-151625
Quarters > 0 > balance Sheet > cash
6089126
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
17208967
Quarters > 0 > balance Sheet > total Current Assets
24611269
Quarters > 0 > balance Sheet > property Plant Equipment
880732
Quarters > 0 > balance Sheet > total Assets
127676859
Quarters > 0 > balance Sheet > payables
10094042
Quarters > 0 > balance Sheet > short Term Debt
229388
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
60115929
Quarters > 0 > balance Sheet > equity
65058550
Quarters > 0 > cash Flow > net Income
-9203872
Quarters > 0 > cash Flow > depreciation
41367
Quarters > 0 > cash Flow > change In Working Capital
771971
Quarters > 0 > cash Flow > cash From Operations
-5406620
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
11469336
Quarters > 0 > cash Flow > net Change In Cash
6062716
Quarters > 0 > ratios > PE
-0.7985786365202324
Quarters > 0 > ratios > PB
0.18948660122305216
Quarters > 0 > ratios > ROE
-13.510709968174822
Quarters > 0 > ratios > ROA
-6.884467607399396
Quarters > 0 > ratios > FCF
-5406620
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
56010
Quarters > 1 > income Statement > gross Profit
-56010
Quarters > 1 > income Statement > operating Expenses
11260678
Quarters > 1 > income Statement > operating Income
-11260678
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-11247265
Quarters > 1 > income Statement > net Income
-10916505
Quarters > 1 > income Statement > eps
-0.9418522847747942
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
11590464
Quarters > 1 > income Statement > income Tax Expense
264240
Quarters > 1 > income Statement > EBITDA
-11191255
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
13413
Quarters > 1 > balance Sheet > cash
26410
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
15339253
Quarters > 1 > balance Sheet > total Current Assets
18374454
Quarters > 1 > balance Sheet > property Plant Equipment
922099
Quarters > 1 > balance Sheet > total Assets
121481411
Quarters > 1 > balance Sheet > payables
9368234
Quarters > 1 > balance Sheet > short Term Debt
145098
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
57905619
Quarters > 1 > balance Sheet > equity
60659412
Quarters > 1 > cash Flow > net Income
-11511505
Quarters > 1 > cash Flow > depreciation
56010
Quarters > 1 > cash Flow > change In Working Capital
3949748
Quarters > 1 > cash Flow > cash From Operations
-4539476
Quarters > 1 > cash Flow > capital Expenditures
4
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
3465807
Quarters > 1 > cash Flow > net Change In Cash
-1073669
Quarters > 1 > ratios > PE
-0.9418522847747942
Quarters > 1 > ratios > PB
0.2140033879655807
Quarters > 1 > ratios > ROE
-17.996391062940077
Quarters > 1 > ratios > ROA
-8.986152622148914
Quarters > 1 > ratios > FCF
-4539480
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
155926
Quarters > 2 > income Statement > cost Of Revenue
54835
Quarters > 2 > income Statement > gross Profit
-54835
Quarters > 2 > income Statement > operating Expenses
10039614
Quarters > 2 > income Statement > operating Income
-10039614
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-10017006
Quarters > 2 > income Statement > net Income
-9768246
Quarters > 2 > income Statement > eps
-0.842782998161247
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
11590464
Quarters > 2 > income Statement > income Tax Expense
264240
Quarters > 2 > income Statement > EBITDA
-9984779
Quarters > 2 > income Statement > operating Margin
-6438.704257147621
Quarters > 2 > income Statement > total Other Income Expense Net
22608
Quarters > 2 > balance Sheet > cash
1100079
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
14381369
Quarters > 2 > balance Sheet > total Current Assets
18327187
Quarters > 2 > balance Sheet > property Plant Equipment
191412
Quarters > 2 > balance Sheet > total Assets
120703457
Quarters > 2 > balance Sheet > payables
7364120
Quarters > 2 > balance Sheet > short Term Debt
204569
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
51783998
Quarters > 2 > balance Sheet > equity
65408079
Quarters > 2 > cash Flow > net Income
-10281246
Quarters > 2 > cash Flow > depreciation
54835
Quarters > 2 > cash Flow > change In Working Capital
2711495
Quarters > 2 > cash Flow > cash From Operations
-4725852
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-5000000
Quarters > 2 > cash Flow > cash From Financing
2574051
Quarters > 2 > cash Flow > net Change In Cash
-2151801
Quarters > 2 > ratios > PE
-0.842782998161247
Quarters > 2 > ratios > PB
0.19846660960643717
Quarters > 2 > ratios > ROE
-14.934311096340256
Quarters > 2 > ratios > ROA
-8.092764070543563
Quarters > 2 > ratios > FCF
-4725852
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-30.30830009106884
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
155926
Quarters > 3 > income Statement > cost Of Revenue
155926
Quarters > 3 > income Statement > gross Profit
-53685
Quarters > 3 > income Statement > operating Expenses
11050478
Quarters > 3 > income Statement > operating Income
-11050478
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-10933164
Quarters > 3 > income Statement > net Income
-10790164
Quarters > 3 > income Statement > eps
-0.9309518583552824
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
11590464
Quarters > 3 > income Statement > income Tax Expense
144000
Quarters > 3 > income Statement > EBITDA
-10996793
Quarters > 3 > income Statement > operating Margin
-7087.00152636507
Quarters > 3 > income Statement > total Other Income Expense Net
117314
Quarters > 3 > balance Sheet > cash
3251880
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
8268766
Quarters > 3 > balance Sheet > total Current Assets
14220646
Quarters > 3 > balance Sheet > property Plant Equipment
246247
Quarters > 3 > balance Sheet > total Assets
116651751
Quarters > 3 > balance Sheet > payables
4927211
Quarters > 3 > balance Sheet > short Term Debt
241547
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
42549921
Quarters > 3 > balance Sheet > equity
70077450
Quarters > 3 > cash Flow > net Income
-11077164
Quarters > 3 > cash Flow > depreciation
53685
Quarters > 3 > cash Flow > change In Working Capital
2325452
Quarters > 3 > cash Flow > cash From Operations
-5912688
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-5000000
Quarters > 3 > cash Flow > cash From Financing
-3746624
Quarters > 3 > cash Flow > net Change In Cash
-14659312
Quarters > 3 > ratios > PE
-0.9309518583552824
Quarters > 3 > ratios > PB
0.18524246644248615
Quarters > 3 > ratios > ROE
-15.39748378401326
Quarters > 3 > ratios > ROA
-9.24989458580866
Quarters > 3 > ratios > FCF
-5912688
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-37.91983376729987
Quarters > 3 > health Score
30
Valuation > metrics > PE
-0.7985786365202324
Valuation > metrics > PB
0.18948660122305216
Valuation > final Score
70
Valuation > verdict
81.1% Undervalued
Profitability > metrics > ROE
-13.510709968174822
Profitability > metrics > ROA
-35.71482640736648
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.9240281100639347
Risk > metrics > Interest Coverage
-51.01535451811775
Risk > final Score
-156
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.384020524186244
Liquidity > metrics > Quick Ratio
0.7170390073841737
Liquidity > final Score
86
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-756
Prev Risks > 1
-1198
Prev Risks > 2
-647
Prev Liquidities > 0
64
Prev Liquidities > 1
76
Prev Liquidities > 2
100
Updated At
2025-12-14T00:22:30.468Z
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACTXR Stock Analysis and Forecast - Chart Pattern Recognition & Grow Generational Wealth With Ease earlytimes.in
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
BUY
Target Price:
$6
Analyst Picks
Strong Buy
1
Buy
0
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 6.65% of the total shares of Citius Pharmaceuticals Inc
1.
UBS Group AG(1.1341%)
since
2025/06/30
2.
CAMBRIDGE Invest RESEARCH ADVISORS, INC.(1.0788%)
since
2025/06/30
3.
Heights Capital Management Inc(0.9399%)
since
2025/06/30
4.
Vanguard Group Inc(0.4709%)
since
2025/06/30
5.
Geode Capital Management, LLC(0.4473%)
since
2025/06/30
6.
Vanguard Institutional Extnd Mkt Idx Tr(0.4114%)
since
2025/07/31
7.
BlackRock Inc(0.4106%)
since
2025/06/30
8.
Fidelity Extended Market Index(0.2988%)
since
2025/07/31
9.
Goss Wealth Management LLC(0.147%)
since
2025/06/30
10.
State Street Corp(0.1368%)
since
2025/06/30
11.
XTX Topco Ltd(0.1184%)
since
2025/06/30
12.
Arkadios Wealth Advisors(0.1176%)
since
2025/06/30
13.
Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors(0.097%)
since
2025/06/30
14.
Northern Trust Corp(0.0845%)
since
2025/06/30
15.
Susquehanna International Group, LLP(0.0835%)
since
2025/06/30
16.
Fidelity Series Total Market Index(0.0834%)
since
2025/07/31
17.
Two Sigma Investments LLC(0.0757%)
since
2025/06/30
18.
Fidelity Total Market Index(0.0685%)
since
2025/07/31
19.
Extended Equity Market Fund K(0.0526%)
since
2025/06/30
20.
Vanguard Instl Ttl Stck Mkt Idx Tr(0.0452%)
since
2024/12/31
21.
IFP Advisors, LLC(0.0416%)
since
2025/06/30
22.
Northern Trust Extended Eq Market Idx(0.0414%)
since
2025/06/30
23.
NT Ext Equity Mkt Idx Fd - L(0.0414%)
since
2025/06/30
24.
Spartan Total Market Index Pool G(0.0343%)
since
2025/07/31
25.
NT Ext Equity Mkt Idx Fd - NL(0.0313%)
since
2025/06/30
26.
Chelsea Management Company(0.0272%)
since
2025/06/30
27.
NT Ext Equity Mkt Idx Fd - DC - NL - T2(0.0243%)
since
2025/06/30
28.
SBI Securities Co Ltd(0.0236%)
since
2025/06/30
29.
NT Ext Eq Mkt Indx Fd DC Lending Tier 5(0.0117%)
since
2025/06/30
30.
State St US Extended Mkt Indx NL Cl C(0.0115%)
since
2025/08/31
31.
Vanguard U.S. Eq Idx £ Acc(0.0105%)
since
2025/07/31
32.
Advisor Group Holdings, Inc.(0.0099%)
since
2025/06/30
33.
NT Ext Eq Mkt Indx Fd DC Lend T3(0.0099%)
since
2024/12/31
34.
Extended Equity Market Fund M(0.0066%)
since
2025/06/30
35.
SSgA U.S. Total Market Index Strategy(0.0048%)
since
2025/03/31
36.
Group One Trading, LP(0.0038%)
since
2025/06/30
37.
State St US Ttl Mkt Indx NL Cl A(0.003%)
since
2025/08/31
38.
Luminist Capital LLC(0.0026%)
since
2025/06/30
39.
Spartan Extended Market Index Pool F(0.0025%)
since
2025/07/31
40.
Northern Trust Wilshire 5000(0.0024%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.